MDACC Study No:2013-0404 (2012-0256 PHASE 1) ( NCT No: NCT01621542)
Title:Initial Phase 1 Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies
Principal Investigator:Jorge Cortes
Treatment Agent:WT2725
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of WT2725 that can be given to patients with advanced cancer. The safety of
WT2725 will also be studied.

WT2725 is a vaccine designed to help your immune system to fight against the
cancer cells by targeting a protein found in cancer cells called WT1. It is
hoped that this may slow down the growth of or kill cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:WT2725
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sunovion Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults